Tonix Pharmaceuticals Holding SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KNov. 9, 2026, 7:20 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedTonix Pharmaceuticals Q3 2026 Revenue of $17.2 Million Beats $16.3 Million Consensus, but GAAP EPS of -$2.89 Misses -$2.24 Estimate
8-KOct. 15, 2026, 7 a.m. ETView on SEC.gov
Results of operations and financial condition · Other events
8-KOct. 2, 2026, 5:20 p.m. ETView on SEC.gov
Other events
8-KSept. 22, 2026, 7:05 a.m. ETView on SEC.gov
Other events · Financial statements and exhibits
8-KSept. 8, 2026, 7:05 a.m. ETView on SEC.gov
Other events · Financial statements and exhibits
8-KAug. 18, 2026, 4 p.m. ETView on SEC.gov
Departure/appointment of directors or officers · Other events
8-KAug. 10, 2026, 7:15 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
8-KAug. 3, 2026, 7:05 a.m. ETView on SEC.gov
Regulation FD disclosure · Other events · Financial statements and exhibits